The rate of HIV infection continues to climb globally. Around 40 million people live with HIV-1, the most common HIV strain. While symptoms can now be better managed with lifelong treatment, there is ...

Expert Rev Proteomics. 2008;5(3):507-528. Although it is widely known that HIV-1 initiates a profound global host cell response to infection, it is difficult to trace specific expression and pathway ...

The FDA granted priority review, with a decision expected by June 19, 2025. LEN represents a novel class of HIV therapies by targeting the viral capsid, a multifunctional protein essential for HIV ...

This is a preview. Log in through your library . Abstract RNA viruses exist as genetically heterogeneous populations due to high mutation rates, and many of these mutations reduce fitness and/or ...

Nucleoside reverse transcriptase translocation inhibitors (NRTTIs) are a novel class of antiretroviral agents that inhibit HIV replication by targeting the viral reverse transcriptase enzyme and ...

For the first time, scientists have captured how new antiviral drugs halt the herpes virus in real time as it tries to replicate.